報價延遲最少15分鐘:2026/08/01 07:00 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.99 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-16.40/-11.69
|
|
企業價值
27.61M
|
| 資產負債 |
|
每股賬面淨值
10.32
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
7.70M
|
|
每股收益
3.53
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment. |
